In short
ELVN-002-1 is an investigational drug currently being studied in clinical trials for the treatment of HER2-positive solid tumors, including colorectal cancer and breast cancer. This article explores the ongoing research on ELVN-002-1 in combination with other cancer treatments, focusing on its potential benefits and safety profile for patients with advanced-stage cancers.
At a glance
- Drug Name
- ELVN-002-1
- Cancer Types
- HER2-positive solid tumors, colorectal cancer, breast cancer
- Administration
- Oral capsules, once or twice daily
- Combination Therapies
- Trastuzumab, CAPEOX, mFOLFOX6, eribulin, capecitabine, paclitaxel
- Study Phases
- Phase 1a and 1b
- Primary Objectives
- Safety, tolerability, recommended dose determination
- Secondary Objectives
- Efficacy assessment, pharmacokinetic profile, anti-tumor activity
- Eligibility
- Adults (18+) with advanced HER2-positive solid tumors
- Key Exclusions
- Severe cardiac issues, active infections, brain metastases requiring immediate therapy
What is ELVN-002-1?
ELVN-002-1 is a new investigational drug being developed by Enliven Therapeutics for the treatment of certain types of cancer. It is currently being studied in a clinical trial to evaluate its safety and effectiveness when used in combination with other cancer treatments.
Target Conditions
ELVN-002-1 is specifically designed to target HER2-positive solid tumors. HER2 (Human Epidermal growth factor Receptor 2) is a protein that promotes the growth of cancer cells. The main conditions being studied in this trial include:
- HER2-positive colorectal cancer (cancer of the colon or rectum)
- HER2-positive breast cancer
- Other HER2-positive solid tumors
How ELVN-002-1 Works
While the exact mechanism of action is not fully described in the trial information, ELVN-002-1 is likely designed to target and inhibit the HER2 protein in cancer cells. By doing so, it may help to slow down or stop the growth of HER2-positive tumors.
Clinical Trial Overview
The clinical trial for ELVN-002-1 is a Phase 1a/1b study, which means it is an early-stage trial primarily focused on assessing the safety of the drug and determining the right dose to use in future studies. The trial is divided into several parts:
- Testing ELVN-002-1 in combination with trastuzumab (another HER2-targeted drug)
- Testing ELVN-002-1 with trastuzumab and various chemotherapy drugs
- Expanding the study to more patients with specific tumor types
Potential Benefits
While it's important to note that ELVN-002-1 is still in early stages of research, the study aims to evaluate several potential benefits:
- Improved effectiveness against HER2-positive tumors when combined with existing treatments
- Possible activity against brain metastases (cancer that has spread to the brain)
- A new option for patients whose cancer has not responded to or has returned after previous treatments
Eligibility Criteria
To participate in this study, patients must meet certain criteria, including:
- Being 18 years or older
- Having a confirmed HER2-positive solid tumor
- Having advanced cancer that has spread or cannot be surgically removed
- Having received certain prior treatments, depending on their cancer type
- Being in relatively good overall health (able to perform daily activities)
Safety Considerations
As with any new treatment, there may be risks and side effects associated with ELVN-002-1. The study is designed to carefully monitor patients for any adverse effects. Some key safety considerations include:
- Patients with certain heart conditions may not be eligible
- The study will monitor for effects on heart function and heart rhythm
- Patients with active infections, liver disease, or certain other medical conditions may be excluded
- The combination with other cancer drugs may have additional side effects
It's important for patients to discuss all potential risks and benefits with their healthcare provider and the study team before considering participation in this or any clinical trial.